



PATENTS  
EL 984 914 702 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: Sanberg, *et al.* : Examiner: To be assigned  
Serial No.: 09/526,403 : Art Unit: 1614  
Filed: March 15, 2000 : Docket No.: T103 F1016.1  
: (Prior Doc. No. L01-03CIP3)

For: Method of Treating Cognitive Deficits in Learning and Memory

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants hereby voluntarily disclose the references listed on the attached Form PTO-1449 to the Commissioner for Patents. This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits of the application. Accordingly, no fees are due.

Copies of the following references are listed on the attached Form PTO-1449 and are enclosed: D3-D4; D7-D10; D12-D14; D17-D20; D26-D28; D33 and D36. References P1 through P11 and References D1-D2; D5-D6; D11; D15-D16; D21-D25; D29-D32; D34-D35 and D37-D43 are listed on the attached Form PTO-1449 and should be available in corresponding Application Nos. 09/198,882 or 08/935,364 as all references were either previously provided by Applicants or were cited by the Examiner. However, Applicants will provide any necessary copies upon request.

Document D7 is a German language document published with an English language abstract. The abstract appears to suggest that the document comprises a discussion of effects of nicotine in the central nervous system, especially in the dopaminergic and cholinergic systems.

This statement should not be construed as the representation that any search has been made, or that the information cited herewith is material, or that there does not exist information more material to the examination of the present Application. The Examiner is specifically requested not to rely solely on the information submitted herein. On the contrary, the Examiner is requested to conduct an independent and thorough review of all available information, and to form independent opinions as to its significance.

Applicants further reserve the right to establish the patentability of the claimed invention over any of the listed information should they be applied as references, and/or to prove that the cited information may not be prior art, and/or to prove that the cited information may not be enabling for the teachings they purport to offer.

The Examiner is respectfully requested to initial and return copies of the enclosed Form PTO-1449 and to indicate in the official file wrapper of the above-identified patent application that each item of the cited information has been considered.

Respectfully submitted,

Date: Dec 5, 2003



Carl B. Massey, Jr.  
Registration No. 44,224  
Attorney for Applicants

Docket: T103 F1016.1

Womble Carlyle Sandridge & Rice, PLLC  
Post Office Box 7037  
Atlanta, Georgia 30357-00378  
Telephone (336) 721-3681  
Facsimile(336) 726-8074



FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DKT NO. T103 F1016.1	SERIAL NO. 09/526,403
				APPLICANT Paul R. Sanberg, et al.	
				FILING DATE 03/15/2000	GROUP
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>					
OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)					
D1	Ballivet, et al., "Nicotine Acetylcholine . . . elegans," JMB., 2296, pp. 261-269 (1996)				
D2	Banerjee, et al., "[ <sup>3</sup> H]Mecamylamine Binding to Rat Brain Membranes," <i>Biochemical Pharmacology</i> , Vol. 40, No. 9, pp. 2105-2110 (1990)				
D3	Bianchi, C. and L. Tomasi, "Central nervous system and autonomic nervous system effects of amantadine and of some standard anti-Parkinson drugs," <i>Pharmacology</i> , 10(4):226-237 (1973).				
D4	Bruun, R.D. and C.L. Budman, "Risperidone as a treatment for Tourette's syndrome," <i>J.Clin. Psychiatry</i> , 57(1): 29-31 (1996).				
D5	Emerich, et al., "Nicotine . . . Locomotor Hypoactivity," <i>Pharm. Biochem. &amp; Behav.</i> , Vol. 38, pp. 875-880 (1991)				
D6	Emerich, et al., "Nicotine . . . of Haloperidol, Psychopharm. Bulletin., Vol. 27(3): 385-390 (1991).				
D7	Erdmann, R., "Nicotine in neuropsychiatric movement disorders," <i>Fortschr Neurol Psychiatr.</i> , 64(9): 362-366 (1996).				
D8	Freund, R.K., et al., "Nicotine effects in mouse hippocampus are blocked by mecamylamine, but not other nicotinic antagonists," <i>Brain Res.</i> , 511(2): 187-191 (1990).				
D9	Ghaemi, S.N., et al., "Acute treatment of bipolar disorder with adjunctive risperidone in outpatients," <i>Can. J. Psychiatry</i> , 42(2): 196-199 (1997).				
D10	Green, M.F., et al., "Does Risperidone Improve Verbal Working Memory in Treatment-Resistant Schizophrenia?" <i>American Journal of Psychiatry</i> , 154(6): 799-804 (1997).				
D11	Hsu, W., "Toxicity and Drug Interactions of Levamisole," <i>HAVMA</i> , Vol. 176, No. 10, pp. 1166-1169 (May 1980)				
D12	Ivanová, S. and A. J. Greenshaw, "Nicotine-induced decreases in VTA electrical self-stimulation thresholds: blockade by haloperidol and mecamylamine but not scopolamine or ondansetron," <i>Psychopharmacology</i> , 134(2): 187-192 (1997).				
D13	Jankovic, J. and H. Rohaidy, "Motor, behavior and pharmacologic findings in Tourette's Syndrome," <i>Can. J. Neurol. Sci.</i> , 14(3 Suppl.): 541-546 (1987).				
D14	Jolles, J., et al., "Cognitive Impairment in Elderly People," <i>Drugs &amp; Aging</i> , 7(6): 459-479 (1995).				
D15	<i>The Lancet</i> , "Nicotine Gum & Haloperidol in Tourette's Syndrome," p. 592 (Mar. 12, 1998)				
D16	<i>The Lancet</i> , "Transdermal nicotine patch . . . in Tourette's Syndrome," Vol. 342, P. 182 (Jul. 17, 1993)				
D17	Levin, E. D. and D. Torry, "Acute and chronic nicotine effects on working memory in aged rats," <i>Psychopharmacology</i> , 123: 88-97 (1996).				
D18	Lindström, E., et al., "Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia," <i>Clin. Ther.</i> 17(3): 402-412 (1995).				
D19	Lombroso, P.J., et al., "Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report," <i>J. Am. Acad. Child Adolesc. Psychiatry</i> , 34(9): 1147-1152 (1995).				
D20	Lomboros, P.J., et al., "Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report," <i>J. Am. Acad. Child Adolesc. Psychiatry</i> , 35(3): 394 (1996).				
D21	McConville, et al., "The Effects . . . in Tourette's Disorder," <i>Biol. Psychiatry</i> , Vol. 31(8): 832-840 (1992)				
D22	McConville, et al., "Nicotine . . . in Tourette's Syndrome," <i>Amer. J. Psychiatry</i> , 148(6): 793-794 (Jun. 1991)				
D23	<i>Pharmacol Ther.</i> , "Nicotine for the Treatment of Tourette's Syndrome," Vol. 74, No. 1, pp. 21-25 (1997)				
D24	<i>Psychopharmacologia</i> (Berl.), "Nicotine-Like . . . after . . . Mecamylamine in . . . rats," 46, pp. 119-121 (1976)				
EXAMINER		DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

MPEP 609 DEC 05 2003 U.S. PATENT & TRADEMARK OFFICE		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DKT NO. T103 F1016.1	SERIAL NO. 09/526,403
				APPLICANT Paul R. Sanberg, et al.	
				FILING DATE 03/15/2000	GROUP
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>					
<b>OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)</b>					
D25	Rupniak, et al. "Antinociceptive and Toxic Effect . . . Attributable to Nicotinic Agonist Activity," <i>Brit. J. Pharmacol.</i> , 113(4): 1487-1493 (1994)				
D26	Sallee, F.R., et al., "Effects of pimozide on cognition in children with Tourette syndrome: interaction with comorbid attention deficit hyperactivity disorder," <i>Acta Psychiatr. Scand.</i> , 90(1): 4-9 (1994).				
D27	Sallee, F.R., et al., "Pharmacokinetics of pimozide in adults and children with Tourette's syndrome," <i>J. Clin. Pharmacol.</i> , 27(10): 776-781 (1987)				
D28	Sallee, F.R., et al., "Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder," <i>Am. J. Psychiatry</i> , 154(8): 1057-1062 (1997).				
D29	Sanberg, et al., "Nicotine as a Therapeutic Adjunct for Tourette's Syndrome," pp. 35-41 (1997)				
D30	Sanberg, et al., "Nicotine . . . with Tourette's Syndrome," <i>Biomed &amp; Pharmacother.</i> , 43, pp. 19-23 (1989)				
D31	Sanberg, et al., "Nicotine . . . Striatal Mechanisms," <i>Pharmacol. Biochem &amp; Behavior</i> , Vol. 46: 303-307 (1993)				
D32	Sano Corporation website (1997)				
D33	Sawada, S., et al., "Augmenting action of nicotine on population spikes in the dentate gyrus of the guinea pig," <i>Neurosci Res.</i> , 20(4): 317-322 (1994).				
D34	Schonenberger, et al., "Preparation of Optically Active . . .," <i>Helvetica Chimica Acta</i> , Vol. 69, pp. 283-287 (1986).				
D35	Seumaru, et al., "Characteristics of tail-tremor induced by nicotine in rats," <i>Naunyn-Schmiedeberg's Arch Pharmacol.</i> , 350:153-157 (1994).				
D36	Shapiro, E., et al., "Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome," <i>Arch. Gen. Psychiatry</i> , 46(8): 722-730 (1989).				
D37	Shieh, et al., "Sexual Differences in the Diurnal Changes . . . of Neuron Activity in Rat: Role of Cholinergic Control," <i>Biology of Reproduction</i> , Vol. 54, pp. 987-992 (1996)				
D38	Shytle, et al., "Nicotine, Tobacco and Addiction," <i>Int'l Weekly Journal of Science</i> , Vol. 384, PP. 18-19 (1997)				
D39	Shytle, et al., "Researchers Exploring . . . TS Treatment," <i>Tourette Syn. Assoc.</i> , 25(1): 1, 3, 7 (1997)				
D40	Shytle, et al., "Transdermal Nicotine for Tourette's Syndrome," <i>Drug Development Research</i> , Vol. 38, pp. 290-298 (1996)				
D41	Silver, et al., "Case Study . . . In Tourette's Syndrome," <i>J. Amer. Child &amp; Adolesc. Psych.</i> , Vol. 35(12), pp. 1631-1636 (1996)				
D42	Stone , et al., "Chemistry and Structure-Activity Relationship of Mecamylamine and Derivatives," <i>Journal of Medicine &amp; Pharm. Chemistry</i> , Vol., 5(4), pp. 665-690 (1962)				
D43	<i>The Merk Index</i> , "5654. Mecamylamine," p. 905 (1989)				
EXAMINER			DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					